公开(公告)号：US20200016143A1

公开(公告)日：2020-01-16

申请号：US16504376

申请日：2019-07-08

Applicant: Novartis AG

Inventor： Rohan Eric John BECKWITH ,  Simone BONAZZI ,  Artiom CERNIJENKO ,  Fupeng MA ,  Nathaniel F. WARE

IPC: A61K31/454 ,  C07D401/14 ,  C07D401/04 ,  A61K31/4545 ,  A61P35/00 ,  A61K31/498

Abstract: The present disclosure provides a compound of Formula (I′): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Ra, Rb, Rx, R1, R2, X2, and q are as defined herein, and methods of making and using same.

公开(公告)号：US20220117945A1

公开(公告)日：2022-04-21

申请号：US17356421

申请日：2021-06-23

Applicant: NOVARTIS AG

Inventor： Rohan Eric John BECKWITH ,  Hua JIANG ,  Ce WANG

IPC: A61K31/422 ,  C07D261/08 ,  C07D413/14 ,  C07D413/04 ,  C07D487/08 ,  C07D413/12 ,  A61P27/16 ,  A61K31/16

Abstract: A compound of Formula (I)) or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating hearing loss or balance disorder: wherein R1 through R3, and L are as defined herein.

公开(公告)号：US20170275243A1

公开(公告)日：2017-09-28

申请号：US15505282

申请日：2015-09-04

Applicant: Novartis AG

Inventor： Rohan Eric John BECKWITH ,  Luis BRITO ,  Brian Addison DECHRISTOPHER ,  Gabriel Grant GAMBER ,  Andrew GEALL ,  Thomas ZABAWA

IPC: C07C219/06 ,  A61K9/127 ,  C07D295/15 ,  C07C219/16 ,  C07C229/12 ,  C07D207/08 ,  A61K47/22 ,  C07C217/58

CPC classification number: C07C219/06 ,  A61K9/1272 ,  A61K9/5123 ,  A61K31/7105 ,  A61K31/711 ,  A61K31/713 ,  A61K47/18 ,  A61K47/22 ,  C07C217/58 ,  C07C219/16 ,  C07C229/12 ,  C07D207/08 ,  C07D211/34 ,  C07D211/62 ,  C07D295/15

Abstract: This invention provides for a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein RA, RB, R2 and R4 are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.